|
Oct 22
|
BMY or VRTX: Which Is the Better Value Stock Right Now?
|
|
Oct 18
|
Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase
|
|
Oct 17
|
Bristol Myers Squibb (BMY) Dips More Than Broader Market: What You Should Know
|
|
Oct 17
|
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
|
|
Oct 17
|
Bristol-Myers Squibb Company (BMY): A Bull Case Theory
|
|
Oct 17
|
Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
|
|
Apr 6
|
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
|
|
Apr 6
|
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies
|
|
Apr 6
|
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
|
|
Apr 5
|
UPDATE 3-US FDA allows expanded use of J&J, Bristol Myers cell therapies
|
|
Apr 5
|
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
|
|
Apr 5
|
Bristol Myers CAR-T therapy approved by FDA for earlier myeloma use
|
|
Apr 4
|
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
|
|
Apr 4
|
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
|
|
Apr 4
|
Merck puts KRAS cancer drug competitor to the test
|
|
Apr 4
|
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.
|
|
Apr 3
|
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
|
|
Apr 3
|
Bristol-Myers Squibb (NYSE:BMY) investors are sitting on a loss of 20% if they invested a year ago
|
|
Apr 3
|
Bristol-Myers Squibb Co's Dividend Analysis
|
|
Apr 3
|
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
|